Article List

WPRIM Management System> DCMS> Clinical and Molecular Hepatology> 2015> 21> 1

Volume: 21 Issue: 1

1. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naive and nucleos(t)ide analogue-experienced chronic hepatitis B patients.	Page:41—48
2. Personalized treatment of hepatitis B.	Page:1—6
3. Clinical implications of advances in liver regeneration.	Page:7—13
4. The cost of liver disease in Korea: methodology, data, and evidence.	Page:14—21
5. Regression of liver cirrhosis: Orthodoxy or paradigm shift?.	Page:22—23
6. Efficacy of prolonged entecavir monotherapy in treatment-naive chronic hepatitis B patients exhibiting a partial virologic response to entecavir.	Page:24—31
7. The factors associated with longitudinal changes in liver stiffness in patients with chronic hepatitis B.	Page:32—40
8. Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.	Page:49—59
9. Fibroblast growth factor receptor isotype expression and its association with overall survival in patients with hepatocellular carcinoma.	Page:60—70
10. Alteration of laboratory findings after radiofrequency ablation of hepatocellular carcinoma: relationship to severity of the underlying liver disease and the ablation volume.	Page:71—79
11. A case of primary hepatic actinomycosis: an enigmatic inflammatory lesion of the liver.	Page:80—84
12. Low-dose steroid-induced tumor lysis syndrome in a hepatocellular carcinoma patient.	Page:85—88
13. Budd-Chiari syndrome with multiple large regenerative nodules.	Page:89—94
14. Recent advances in the imaging of hepatocellular carcinoma.	Page:95—103